CBD (cannabidiol) is a non-intoxicating cannabinoid, and with THC one of the two most abundant in cannabis. It starts life as an acid: an enzyme called CBDA synthase builds CBDA from the precursor CBGA (Taura 1996), and heat later turns CBDA into CBD. Formula C21H30O2, CAS 13956-29-1.
C21H30O2 · MW ≈ 314.46 · CAS 13956-29-1 · non-intoxicating · a structural isomer of Δ9-THC · made in the plant as CBDA (from CBGA, by CBDA synthase) and converted to CBD by heat
Forms from CBDA. Nothing on the map forms from it.
42 questions, and 29 of them earn a verified grade on the six-rung evidence ladder. 13 carry an evidence state instead of a rung, and most of those read no primary evidence: our registry has no study on the question, a different finding from not supported and marked differently.
CBD has far more human research behind it than any minor cannabinoid, but our registry has not yet graded those trials. So the answers state as fact, each with an evidence grade, only what CBD is, how the plant makes it, how it behaves at receptors in the lab, and that it is non-intoxicating. Effects appear as claims made by others, with their limits. CBG Atlas does not make, adopt, or affirm these claims. Not medical or legal advice.
CBD (cannabidiol) is a non-intoxicating cannabinoid, and with THC one of the two most abundant in cannabis. It starts life as an acid: an enzyme called CBDA synthase builds CBDA from the precursor CBGA (Taura 1996), and heat later turns CBDA into CBD. Formula C21H30O2, CAS 13956-29-1.
Cannabidiol. CBD shares THC's molecular formula, C21H30O2, and a molecular weight of about 314.46, with the atoms arranged differently, which makes the two structural isomers. That rearrangement shows up in the body. THC activates the CB1 receptor, the source of its high, and CBD does not (Pertwee 2008).
From CBGA, by way of an acid: the plant makes CBDA first, and CBD comes later. The enzyme CBDA synthase converts the precursor CBGA into CBDA (Taura 1996), and CBDA becomes CBD when heat strips off a carboxyl group. The rate of that step, decarboxylation, has been measured in the laboratory across a range of temperatures (Wang 2016).
CBDA (cannabidiolic acid) is the form of CBD the living plant actually makes. CBDA synthase produces it from CBGA (Taura 1996), and the enzyme is less than perfectly specific, since it also yields a little CBCA (Zirpel 2018). Raw plant material carries mostly CBDA; heating, drying and processing convert it to CBD.
No. Hemp is the plant; CBD is one of the compounds it makes. US law defines hemp as cannabis with at most 0.3% Δ9-THC by dry weight, a definition that is all about THC and silent on CBD. So "hemp oil" on a label is a poor guide to CBD content, which may or may not be meaningful; the certificate of analysis (COA) is where to check.
No. THC's high comes from activating the CB1 receptor, and CBD does not activate it that way: in laboratory studies it instead reduces how strongly other compounds activate CB1 (Pertwee 2008; Laprairie 2015). The one caveat sits in the product, since full-spectrum CBD contains trace THC.
That depends on the definition. In laboratory studies CBD acts on brain receptors, activating the serotonin 5-HT1A receptor at modest strength (Russo 2005) and reducing activation of CB1 (Laprairie 2015), yet it produces no intoxication. So CBD is active in the nervous system without getting anyone high, and what that means for effects in people is still unsettled.
It may, in a dish. Cell studies show CBD reduces how strongly other compounds activate the CB1 receptor (Pertwee 2008; Laprairie 2015), and that finding underlies the popular idea that CBD takes the edge off THC. Whether that holds in people, at the amounts found in consumer products, is a question our registry has not yet graded.
Broadly yes at the federal level, for hemp-derived CBD at or below 0.3% Δ9-THC by dry weight, under the 2018 Farm Bill. Each state sets its own rules, and they differ. The catch for anyone formulating a food or supplement: the FDA has not approved CBD as a food additive or a dietary supplement. General, dated information rather than legal advice.
No, and the map keeps moving. Rules differ by country, and in the US by state. Some places allow hemp-derived CBD products, some restrict CBD to prescription, and some limit or ban it. Check the local rules before you buy CBD or pack it for a trip. General information rather than legal advice.
Yes, one. A purified-CBD prescription medicine is approved for certain rare seizure disorders and is used under a doctor's supervision. The approval covers that one medicine and stops there: consumer CBD products carry no approval to treat any condition, so a consumer brand has nothing to borrow for a label claim.
Calm, sleep, stress, pain and general wellness, if you go by the marketing, and those claims belong to sellers and users. The only use regulators have accepted is the prescription medicine for certain rare seizure disorders. For consumer products the benefits are not established: human trials exist, and our registry has not yet checked and graded them.
The question is open: our registry has not yet graded the published human studies of CBD and anxiety, so it makes no claim either way, however widely CBD is marketed for anxiety. We do not summarise studies we have not checked. The practical point is interactions. CBD can interact with anxiety medicines and others, so talk to a clinician before combining them. (Not medical advice.)
Still ungraded: human studies exist, and our registry has not yet assessed any of them. Sleep is one of the most common reasons people buy CBD, a demand built on marketing and anecdote rather than a finding we can grade. If sleep is the goal, CBN, often sold for it, is the cautionary tale: tested in people, it missed its pre-specified sleep endpoints. (Not medical advice.)
Our registry has not graded CBD for pain or inflammation, so we state no effect, even though these are among the most common claims made for it. Laboratory and animal work on cannabinoids and inflammation exists, and some human studies have been published. A product label is no reason to stop or replace prescribed pain treatment. (Not medical advice.)
Only in one form: a purified-CBD prescription medicine approved for certain rare seizure disorders and used under a doctor's supervision. Consumer CBD products are no epilepsy treatment and must never replace prescribed anti-seizure medicine. The approval covers neither over-the-counter CBD nor CBDV, whose own seizure trial failed to beat placebo (Brodie 2021).
A hypothesis, so far: the idea that cannabinoids and terpenes work better together than apart. Widely marketed, it has not been established in people. Individual compounds have verified laboratory activity, while the combined effect remains unshown, so "works better as full-spectrum" is a claim running ahead of the evidence. Our explainer on receptors and the entourage effect sets out what is known.
CBD is non-intoxicating, which is a different thing from risk-free. It can change how the liver processes other medicines, and the approved CBD medicine carries warnings about liver effects and drug interactions. The long-term safety of everyday consumer use is poorly characterised. If you take other medication, talk to a clinician. (Not medical advice.)
Yes, it can. CBD affects the CYP450 liver enzymes that break down many medicines, and so can change their levels in the blood, one reason the approved CBD medicine carries interaction and liver-monitoring warnings. Medicines that come with a grapefruit warning need particular care. Ask a doctor or pharmacist before combining CBD with any prescription medicine. (Not medical advice.)
Many people do, but daily use has run ahead of the safety data: the long-term safety of CBD in the general population is poorly established. Regulators have pointed to possible liver effects at higher intakes, and to drug interactions, as reasons for care. Anyone using it regularly, especially alongside other medication, is best off doing so with a clinician's guidance. (Not medical advice.)
Best avoided. The FDA advises against CBD, THC or marijuana in any form during pregnancy or breastfeeding, citing unknown risks and limited safety data. No safe amount has been established, and products can contain trace THC and contaminants. Talk with your obstetrician before using any CBD product. (Not medical advice.)
Only under medical supervision. The one route with a doctor attached is the purified-CBD prescription medicine, approved for certain rare seizure disorders, including in children, and given under a doctor's oversight. An over-the-counter bottle from the shelf is another matter entirely, because its safety in children has not been established. Talk to a paediatrician first. (Not medical advice.)
The evidence is too thin to call it safe for pets. Some CBD products are sold for animals, yet veterinary evidence and safe dosing remain limited. Products made for people bring hazards of their own: they may contain trace THC, which is toxic to dogs, or additives such as xylitol that are toxic to pets. Ask a veterinarian before giving CBD to an animal. (Not medical advice.)
Possibly, but that has not been established. Some early research has looked at CBD and cardiovascular measures, blood pressure among them, and what it found is preliminary. If you take blood-pressure or heart medication, talk to a clinician before using CBD. (Not medical advice.)
The evidence is thin either way. Tolerance to THC is documented, while good human data on tolerance to CBD are limited. If a product seems to fade over time, take that to a clinician rather than taking more. (Not medical advice.)
Many broad- and full-spectrum products already contain both, and some people combine them. No controlled human study has shown that the pair does more than either compound alone. CBG acts on α2-adrenoceptors, which help regulate blood pressure (Cascio 2010), so talk to a clinician first if you take cardiovascular medication. (Not medical advice.)
CBD itself generally goes unseen, because standard drug tests screen for THC. The trouble is the THC that rides along: trace amounts in full-spectrum and some broad-spectrum products can build up with regular use and trigger a positive result. Isolate lowers that risk, but no product is guaranteed to pass, so check the certificate of analysis before you rely on it.
A single reliable figure is out of reach, because the answer turns on the amount, how often you use it, the product and your body. Published human data for consumer products are too limited to support a number. For a drug test the clock that matters is THC's, since full-spectrum products contain trace THC that can accumulate.
CBD itself sits outside the World Anti-Doping Agency's prohibited list; the risk lives in the products. Prohibited cannabinoids, including THC and CBDV, can turn up in CBD products. Isolate lowers that risk, though no product is guaranteed clean. Check your own governing body's rules before using any CBD product.
There is no established dose for consumer CBD, and we do not publish one. The number on the label is the seller's choice rather than evidence we can grade, and the prescription CBD medicine is dosed by a doctor for specific conditions, a different exercise altogether. If you use CBD, talk to a clinician or pharmacist first, especially if you take other medicines. (Not medical advice.)
What else comes along with the CBD. Full-spectrum keeps the hemp plant's range of compounds, trace THC included. Broad-spectrum is processed to strip out THC while keeping the rest, though traces can survive. Isolate is purified CBD alone. For a buyer the choice matters most at the drug test; claims that one type works better lean on the unproven entourage idea.
Oils and tinctures taken by mouth, capsules, gummies and drinks, creams and balms for the skin, and vapes. Published human data comparing these consumer forms are too few to rank them. Vapes carry their own risks from the device and any additives, whatever cannabinoid they contain.
THC intoxicates and CBD does not, although they share a formula, C21H30O2. The split happens at the receptor, where THC activates CB1 (Pertwee 2008) and CBD fails to. The law divides them too: in the US, THC is federally controlled while hemp-derived CBD is broadly legal at the federal level, and drug tests look for THC. Our CBD vs THC comparison has the details.
Both are non-intoxicating and both descend from CBGA, by different routes: CBG is CBGA's neutral form, while CBD comes from CBDA, which the plant builds from CBGA. At the serotonin 5-HT1A receptor they pull in opposite directions, with CBD activating it and CBG blocking it (Russo 2005). CBG's α2-adrenoceptor activity is why it carries a blood-pressure caution (Cascio 2010).
They form differently. The plant makes CBD with an enzyme, while CBN is a breakdown product that forms when THC oxidises with age, heat and light. CBN is sold for sleep, yet in people it missed its pre-specified sleep endpoints. CBD is non-intoxicating, and CBN is at most weakly active at cannabinoid receptors. Our CBN vs CBD comparison has the details.
No. CBDV (cannabidivarin) is CBD's propyl relative, with a side chain two carbons shorter, and CBD's clinical record stays with CBD. The approved seizure medicine is purified CBD, while the trial that tested CBDV for seizures failed to beat placebo (Brodie 2021). Our CBDV vs CBD comparison has the details.
THCA is THC's raw acid: non-intoxicating as it stands, but heat turns it into THC, which intoxicates. CBD is non-intoxicating, heated or raw. THCA products are often sold as hemp because of the way some laws count THC before it is heated. Our THCA vs CBD comparison has the details.
In laboratory studies CBD damps CB1 activation instead of producing it. It acts as a negative allosteric modulator of CB1 (Laprairie 2015), blocks compounds that activate CB1 and CB2 (Pertwee 2008), and activates the serotonin 5-HT1A receptor at modest strength (Russo 2005). Every one of those findings comes from cells; effects in people are a separate question.
CBD's formula is C21H30O2, its molecular weight about 314.46, and its CAS number 13956-29-1. A structural isomer of Δ9-THC, it has the same atoms in a different arrangement. The plant makes it as the acid CBDA, which loses a carboxyl group to become CBD.
Usually by extracting hemp and heating it, so the plant's CBDA converts to CBD, a step whose rate has been measured in the laboratory (Wang 2016). From there the paths split. Isolate goes through further purification; full- and broad-spectrum extracts keep more of the plant's other compounds. The batch's certificate of analysis tells you which one you actually have.
Start with the certificate of analysis (COA), and judge the brand by it. A good one is recent, batch-specific and from an independent lab; it confirms the CBD content and THC level and screens for pesticides, solvents, heavy metals and microbes. Favour brands that publish COAs openly and keep disease claims off the label. A label that promises a health outcome is a warning sign. (Not medical advice.)
A lab report for a single batch of a product, and the most useful document a buyer can ask for. It should name the lab, the batch number and the test date, list the measured cannabinoid content (CBD and THC), and report contaminant screening. A batch number that fails to match the product, or a missing COA, is reason to read the product's claims with caution.
Informational only, not medical advice. CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Every claim on the page carries the grade of the evidence behind it, and the grade sets the words the claim may use. How we grade evidence.
Educational, not medical or legal advice. Statements about effects, benefits or uses report claims made by third parties. CBG Atlas does not make, adopt or affirm them. Legal status depends on jurisdiction, product class and date, and it changes, so check it against the official source. See how we grade and the safety page.
Cardiovascular note. CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.
Funding and independence. Peregrine Biopharma funds the platform and holds no editorial authority.
Report a safety event →Families
Its varin or pentyl analogue
Head-to-head